Significantly improve the motor symptoms of patients with Parkinson's disease, phase 2 clinical results are positive

Anavex Life Sciences announced that its investigational therapy Anavex 2-73 has achieved positive results in a Phase 2 clinical trial for patients with Parkinson's disease dementia

Anavex 2-73 is a sigma-1 receptor (SIGMAR1) agonist

In this phase 2 randomized, double-blind, placebo-controlled phase 2 clinical trial, 132 patients with Parkinson's disease dementia received different doses of Anavex 2-73 or placebo

The results of the trial showed that compared with placebo, the MDS-UPDRS (a score for evaluating the motor function of patients with Parkinson's disease) in the Anavex 2-73 high-dose group showed a statistically significant improvement

Anavex 2-73 treatment also resulted in a significant increase in SIGMAR1 mRNA expression (p=0.

"This is currently the second independent phase 2 clinical trial to

Reference materials:

[1] Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson's Disease Dementia.

[2] Anavex Corporate Presentation.